Skip to main content
Top
Published in: Clinical Journal of Gastroenterology 3/2012

01-06-2012 | Case Report

Overlap syndrome of autoimmune hepatitis and primary sclerosing cholangitis complicated with hepatocellular carcinoma

Authors: Kazuto Fukuda, Sachiyo Kogita, Yusuke Tsuchimoto, Yoshiyuki Sawai, Takumi Igura, Hideko Ohama, Yuki Makino, Yasushi Matsumoto, Masanori Nakahara, Shin-ichirou Zushi, Yasuharu Imai

Published in: Clinical Journal of Gastroenterology | Issue 3/2012

Login to get access

Abstract

Development of hepatocellular carcinoma (HCC) in patients with autoimmune liver disease is less common than in those with other types of chronic liver disease. Here we report a rare case of overlap syndrome consisting of autoimmune hepatitis (AIH) and primary sclerosing cholangitis (PSC) that was subsequently complicated with HCC. A 72-year-old man was initially diagnosed as being in the cirrhotic stage of AIH on the basis of blood chemistry tests and histological examinations. Computed tomography and magnetic resonance cholangiography 20 months later showed diffuse stricturing of the intrahepatic bile duct with dilatation of the areas between the strictures, compatible with the findings of PSC, which resulted in a diagnosis of AIH/PSC overlap syndrome. The level of serum protein induced by vitamin K absence or antagonist II increased 22 months later, and HCC was diagnosed by radiological examinations. Four cycles of transarterial infusion therapy with cisplatin were performed, but the patient died one year later. Sequential overlap of PSC may have played a part in accelerating AIH disease progression, leading to the development of HCC in this patient. Therefore, HCC surveillance may be important in advanced stages of autoimmune disease, especially in the cirrhotic stage.
Literature
1.
go back to reference Czala AL, Manns MP. Advances in the diagnosis, pathogenesis, and management of autoimmune hepatitis. Gastroenterology. 2010;139:58–72.CrossRef Czala AL, Manns MP. Advances in the diagnosis, pathogenesis, and management of autoimmune hepatitis. Gastroenterology. 2010;139:58–72.CrossRef
2.
go back to reference Chapman R, Fevery J, Kalloo A, Nagorney DM, Boberg KM, Shneider B, et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology. 2010;51:660–78.PubMedCrossRef Chapman R, Fevery J, Kalloo A, Nagorney DM, Boberg KM, Shneider B, et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology. 2010;51:660–78.PubMedCrossRef
3.
go back to reference Kaya M, Angulo P, Lindor KD. Overlap of autoimmune hepatitis and primary sclerosing cholangitis: an evaluation of a modified scoring system. J Hepatol. 2000;33:537–42.PubMedCrossRef Kaya M, Angulo P, Lindor KD. Overlap of autoimmune hepatitis and primary sclerosing cholangitis: an evaluation of a modified scoring system. J Hepatol. 2000;33:537–42.PubMedCrossRef
4.
go back to reference Floreani A, Rizzotto ER, Ferrara F, Carderi I, Caroli D, Blasone L, et al. Clinical course and outcome of autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome. Am J Gastroenterol. 2005;100:1516–22.PubMedCrossRef Floreani A, Rizzotto ER, Ferrara F, Carderi I, Caroli D, Blasone L, et al. Clinical course and outcome of autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome. Am J Gastroenterol. 2005;100:1516–22.PubMedCrossRef
5.
go back to reference Lüth S, Kanzler S, Frenzel C, Kasper HU, Dienes HP, Schramm C, et al. Characteristics and long-term prognosis of the autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome. J Clin Gastroenterol. 2009;43:75–80.PubMedCrossRef Lüth S, Kanzler S, Frenzel C, Kasper HU, Dienes HP, Schramm C, et al. Characteristics and long-term prognosis of the autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome. J Clin Gastroenterol. 2009;43:75–80.PubMedCrossRef
6.
go back to reference Bruix J, Sherman M. AASLD practice guideline. Management of hepatocellular carcinoma: an update. Hepatology. 2011;3:1020–2.CrossRef Bruix J, Sherman M. AASLD practice guideline. Management of hepatocellular carcinoma: an update. Hepatology. 2011;3:1020–2.CrossRef
7.
go back to reference Yeoman AD, Al-Chalabi T, Karani JB, Quaglia A, Devlin J, Mieli-Vergani G, et al. Evaluation of risk factors in the development of hepatocellular carcinoma in autoimmune hepatitis: implications for follow-up and screening. Hepatology. 2008;48:863–70.PubMedCrossRef Yeoman AD, Al-Chalabi T, Karani JB, Quaglia A, Devlin J, Mieli-Vergani G, et al. Evaluation of risk factors in the development of hepatocellular carcinoma in autoimmune hepatitis: implications for follow-up and screening. Hepatology. 2008;48:863–70.PubMedCrossRef
8.
go back to reference Wong RJ, Gish R, Frederick T, Bzoweji N, Frenette C. Development of hepatocellular carcinoma in autoimmune hepatitis patients: a case series. Dig Dis Sci. 2011;56:578–85.PubMedCrossRef Wong RJ, Gish R, Frederick T, Bzoweji N, Frenette C. Development of hepatocellular carcinoma in autoimmune hepatitis patients: a case series. Dig Dis Sci. 2011;56:578–85.PubMedCrossRef
9.
go back to reference Hennes EM, Zeniya M, Czaja AJ, Pares A, Dalekos GN, Krawitt EJ, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology. 2008;48:169–76.PubMedCrossRef Hennes EM, Zeniya M, Czaja AJ, Pares A, Dalekos GN, Krawitt EJ, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology. 2008;48:169–76.PubMedCrossRef
10.
go back to reference Gregorio GV, Portmann B, Karani J, Harrison P, Donaldson PT, Vergani D, et al. Autoimmune hepatitis/sclerosing overlap syndrome in childhood: a 16-year prospective study. Hepatology. 2001;33:544–53.PubMedCrossRef Gregorio GV, Portmann B, Karani J, Harrison P, Donaldson PT, Vergani D, et al. Autoimmune hepatitis/sclerosing overlap syndrome in childhood: a 16-year prospective study. Hepatology. 2001;33:544–53.PubMedCrossRef
11.
go back to reference Abdalian R, Dhar P, Jhaveri K, Haider M, Guindi M, Heathcote EJ. Prevalence of sclerosing cholangitis in adults with autoimmune hepatitis: evaluating the role of routine magnetic resonance imaging. Hepatology. 2008;47:949–57.PubMedCrossRef Abdalian R, Dhar P, Jhaveri K, Haider M, Guindi M, Heathcote EJ. Prevalence of sclerosing cholangitis in adults with autoimmune hepatitis: evaluating the role of routine magnetic resonance imaging. Hepatology. 2008;47:949–57.PubMedCrossRef
12.
go back to reference Lewin M, Vilgrain V, Ozenne V, Lemoine M, Wendum D, Paradis V, et al. Prevalence of sclerosing cholangitis in adults with autoimmune hepatitis: a prospective magnetic resonance imaging and histological study. Hepatology. 2009;50:528–37.PubMedCrossRef Lewin M, Vilgrain V, Ozenne V, Lemoine M, Wendum D, Paradis V, et al. Prevalence of sclerosing cholangitis in adults with autoimmune hepatitis: a prospective magnetic resonance imaging and histological study. Hepatology. 2009;50:528–37.PubMedCrossRef
13.
go back to reference Abdo AA, Bain VG, Kichian K, Lee SS. Evolution of autoimmune hepatitis to primary sclerosing cholangitis: a sequential syndrome. Hepatology. 2002;36:1393–9.PubMed Abdo AA, Bain VG, Kichian K, Lee SS. Evolution of autoimmune hepatitis to primary sclerosing cholangitis: a sequential syndrome. Hepatology. 2002;36:1393–9.PubMed
14.
go back to reference Buuren HR, Hoogstraten HJF, Terkivatan T, Schalm SW, Vleggaar FP. High prevalence of autoimmune hepatitis among patients with primary sclerosing cholangitis. J Hepatol. 2000;33:543–8.PubMedCrossRef Buuren HR, Hoogstraten HJF, Terkivatan T, Schalm SW, Vleggaar FP. High prevalence of autoimmune hepatitis among patients with primary sclerosing cholangitis. J Hepatol. 2000;33:543–8.PubMedCrossRef
15.
go back to reference Takikawa H, Manabe T. Primary sclerosing cholangitis in Japan-analysis of 192 cases. J Gastroenterol. 1997;32:919–35.CrossRef Takikawa H, Manabe T. Primary sclerosing cholangitis in Japan-analysis of 192 cases. J Gastroenterol. 1997;32:919–35.CrossRef
16.
go back to reference Takiguchi J, Ohira H, Rai T, Shishido S, Tojo J, Sato Y, et al. Autoimmune hepatitis overlapping with primary sclerosing cholangitis. Intern Med. 2002;41:696–700.PubMedCrossRef Takiguchi J, Ohira H, Rai T, Shishido S, Tojo J, Sato Y, et al. Autoimmune hepatitis overlapping with primary sclerosing cholangitis. Intern Med. 2002;41:696–700.PubMedCrossRef
17.
go back to reference Montano-Loza AJ, Carpenter HA, Czaja AJ. Predictive factors for hepatocellular carcinoma in type 1 autoimmune hepatitis. Am J Gastroenterol. 2008;103:1944–51.PubMedCrossRef Montano-Loza AJ, Carpenter HA, Czaja AJ. Predictive factors for hepatocellular carcinoma in type 1 autoimmune hepatitis. Am J Gastroenterol. 2008;103:1944–51.PubMedCrossRef
18.
go back to reference Burak K, Angulo P, Pasha TM, Egan K, Petz J, Lindor KD. Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol. 2004;99:523–6.PubMedCrossRef Burak K, Angulo P, Pasha TM, Egan K, Petz J, Lindor KD. Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol. 2004;99:523–6.PubMedCrossRef
19.
go back to reference Prytz H, Keiding S, Bjornsson E. Dynamic FDG-PET is useful for detection of cholangiocarcinoma in patients with PSC listed for liver transplantation. Hepatology. 2006;44:1572–80.PubMedCrossRef Prytz H, Keiding S, Bjornsson E. Dynamic FDG-PET is useful for detection of cholangiocarcinoma in patients with PSC listed for liver transplantation. Hepatology. 2006;44:1572–80.PubMedCrossRef
20.
go back to reference Harnois DM, Gores JG, Ludwig J, Steers JL, LaRusso NE, Wiesner RH. Are patients with cirrhotic stage primary sclerosing cholangitis at risk for the development of hepatocellular cancer? J Hepatol. 1997;27:512–6.PubMedCrossRef Harnois DM, Gores JG, Ludwig J, Steers JL, LaRusso NE, Wiesner RH. Are patients with cirrhotic stage primary sclerosing cholangitis at risk for the development of hepatocellular cancer? J Hepatol. 1997;27:512–6.PubMedCrossRef
21.
go back to reference Leidenius M, Hockersted K, Broome U, Ericzon BG, Friman S, Olauson M, et al. Hepatobiliary carcinoma in primary sclerosing cholangitis: a case control study. J Hepatol. 2001;34:792–8.PubMedCrossRef Leidenius M, Hockersted K, Broome U, Ericzon BG, Friman S, Olauson M, et al. Hepatobiliary carcinoma in primary sclerosing cholangitis: a case control study. J Hepatol. 2001;34:792–8.PubMedCrossRef
22.
go back to reference Maeda C, Tamano M, Murohisa T, Yamagishi T, Hashimoto T, Kojima K, et al. Hepatocellular carcinoma associated with noncirrhotic autoimmune hepatitis. Clin J Gastroenterol. 2010;3:111–5.CrossRef Maeda C, Tamano M, Murohisa T, Yamagishi T, Hashimoto T, Kojima K, et al. Hepatocellular carcinoma associated with noncirrhotic autoimmune hepatitis. Clin J Gastroenterol. 2010;3:111–5.CrossRef
Metadata
Title
Overlap syndrome of autoimmune hepatitis and primary sclerosing cholangitis complicated with hepatocellular carcinoma
Authors
Kazuto Fukuda
Sachiyo Kogita
Yusuke Tsuchimoto
Yoshiyuki Sawai
Takumi Igura
Hideko Ohama
Yuki Makino
Yasushi Matsumoto
Masanori Nakahara
Shin-ichirou Zushi
Yasuharu Imai
Publication date
01-06-2012
Publisher
Springer Japan
Published in
Clinical Journal of Gastroenterology / Issue 3/2012
Print ISSN: 1865-7257
Electronic ISSN: 1865-7265
DOI
https://doi.org/10.1007/s12328-012-0294-5

Other articles of this Issue 3/2012

Clinical Journal of Gastroenterology 3/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.